Revenues leap at Oxford Pharmascience
Oxford Pharmascience saw revenues jump in the first half after it signed a sales deal with one of Brazil's largest pharmaceutical companies.
Oxford Pharmascience saw revenues jump in the first half after it signed a sales deal with one of Brazil's largest pharmaceutical companies.
Revenues came in at £341,000, up from £20,000 the year before, with sales to Brazil's Ach making up the lions share.
The pharmaceutical technology company cut its pre-tax loss to £399,000, from £501,000 in the first half of 2011, with loss per share coming in at 0.07p.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Chairman David Norwood said 2011 was a breakthrough year for the company having changed its focus to the higher value pharmaceutical market.
"The commencement of sales to Ach, one of Brazil's largest pharmaceutical companies and the launch of its OXP zero taste masking technology left [the company] well placed going into this year," he said.
-
FTSE 100 hits record highs – why is it rising and will we see more gains?
Advice UK equities have been described as unloved for a long time but as the FTSE 100 hits new highs, we explain if now is the time to buy British.
By Marc Shoffman Published
-
How to invest in copper
It may be time to invest in copper as the red metal appears poised for a big jump. Dominic Frisby looks at what should investors should buy
By Dominic Frisby Published